& Prosper Trading Academy
Whoo! Crazy stuff going on in the markets today! 😱 In response to the trade wars that appear to be shaping up… Dow futures dropped 800 points. S&P 500 & Nasdaq? Both dropped more than 3%, signaling some serious market jitters. 😬
Hold on to your hats! Going to be a rocky one.
Not everybody’s losing though… see who’s shining today in a sea of red!
FOCUS LIST🔎
CHSN – Up over 150% in the pre-market after reporting better than expected fiscal year 2024 financial results
LXEO – Up over 13% in pre after announcing positive interim phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy supporting advancement to registrational study
YCBD- Up over 15% in pre after announcing it has achieved key milestone in UK novel food regulatory approval
Receive Honest News Today
Join over 4 million Americans who start their day with 1440 – your daily digest for unbiased, fact-centric news. From politics to sports, we cover it all by analyzing over 100 sources. Our concise, 5-minute read lands in your inbox each morning at no cost. Experience news without the noise; let 1440 help you make up your own mind. Sign up now and invite your friends and family to be part of the informed.
HOTLIST🔥
CHSN – Up over 150% in the pre-market after reporting better than expected fiscal year 2024 financial results
Chanson International Holding (CHSN) is a provider of bakery, seasonal, and beverage products through its chain stores in China and the United States.
Over the weekend, the company announcedits financial results for the fiscal year ended December 31, 2024.
Highlights include:
Total revenue was $18.2 million, an increase of 5.7% from $17.3 million in fiscal year 2023.
Gross profit was $7.2 million, compared to $8.1 million in fiscal year 2023.
Gross margin was 39.5%, compared to 47.2% in fiscal year 2023.
Net income was $0.76 million, increased from $0.03 million in fiscal year 2023.
Basic and diluted earnings per share were $0.05, increased from $0.003 in fiscal year 2023.
Shares of CHSN traded up over 150% in the pre-market in reaction to the news.
The $0.50 area acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $0.58, $0.63 and then the pre-market high at $0.6490. Beyond that, $0.78, $1 and $1.50 come into play.
Below $0.50, targets to the downside are $0.46, $0.35, $0.25 and then a gap fill at $0.2190.
LXEO – Up over 13% in pre after announcing positive interim phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy supporting advancement to registrational study
Lexeo Therapeutics Inc. (LXEO) is a clinical stage genetic medicine company that focuses on hereditary and acquired diseases with high unmet need in the United States.
In the pre-market this morning, the company announcedpositive interim data across all dose cohorts of LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy.
Highlights include:
-Participants with abnormal left ventricular mass index (LVMI) at baseline achieved 25% mean reduction in LVMI by 12 months or sooner
-Clinically meaningful improvements in majority of participants across cardiac biomarkers and functional measures
-All SUNRISE-FA participants achieved meaningful increases in frataxin expression at 3-months post treatment; 115% average cardiac frataxin expression increase in high dose cohort, demonstrating dose response
-Frataxin expression and LVMI improvement exceed co-primary target thresholds for planned registrational study
Shares of LXEO traded up over 13% in the pre-market in reaction to the news.
The $2.55 area acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $2.80, $2.99 and then the pre-market high at $3.05. Beyond that, $3.20, $3.33 and $3.80 come into play.
Below $2.55, targets to the downside are $2.47, $2.40 and then a gap fill at $2.34.
YCBD- Up over 15% in pre after announcing it has achieved key milestone in UK novel food regulatory approval
cbdMD, Inc. (YCBD) is a leader in premium hemp-derived cannabidiol (CBD) products.
In the pre-market this morning, the company announced that its Novel Food dossier (RP793) has advanced to the last phase of regulatory assessment with the UK Food Standards Agency (FSA), nearing final approval.
cbdMD initiated this process in March 2021, with the submission of a comprehensive dossier detailing the ingredient’s identity, quality, stability, hemp sourcing, extraction controls, labeling, testing requirements, usage instructions, and extensive safety data.
In February 2022, cbdMD became the first U.S. brand to receive dossier validation. Since then, cbdMD has worked closely with the FSA, actively addressing inquiries to expedite the regulatory review process.
Shares of YCBD traded up over 15% in the pre-market in reaction to the news.
The $0.24 area acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $0.28 and then the pre-market high at $0.3017. Beyond that, $0.33, $0.36 and $0.42 come into play.
Below $0.24, targets to the downside are $0.22, $0.20 with all-time lows below that.
MARKET NEWS 📰
U.S. Stock Market Performance:
Dow Jones Industrial Average: Futures dropped approximately 800 points, reflecting investor concerns over the new trade policies. Investopedia+1WSJ+1
S&P 500 and Nasdaq-100: Both indices saw futures declines exceeding 3%, highlighting widespread market apprehension. WSJ
Bear Market Indicators: The S&P 500 is now nearly 20% below its peak, signaling a potential bear market. Latest news & breaking headlines
International Market Reactions:
Asia: Markets were notably affected, with Hong Kong’s Hang Seng Index plummeting 13.2%, Taiwan’s Taiex falling 9.7%, and Japan’s Nikkei experiencing an 8% drop. Latest news & breaking headlines
Europe: The FTSE 100 declined over 4.5%, and the pan-European Stoxx 600 index decreased by 5%, as investors reacted to the escalating trade tensions. Latest news & breaking headlines+1Investopedia+1
Cryptocurrency Market:
Bitcoin: The cryptocurrency market also felt the impact, with Bitcoin falling to approximately $78,000, marking its lowest level since November. Investopedia+1LatestLY+1
Economic Outlook:
Recession Concerns: Goldman Sachs revised its U.S. GDP growth forecast for Q4 2025 down to 0.5% and increased its recession probability estimate from 35% to 45%. Investopedia
Federal Reserve Actions: Investors anticipate potential aggressive interest rate cuts from the Federal Reserve, possibly up to five 25-basis-point reductions in 2025, in response to the economic uncertainty. Latest news & breaking headlines
DISCLAIMER: To more fully understand any Ragingbull.com, LLC (“RagingBull”) subscription, website, application or other service (“Services”), please review our full disclaimer located at https://ragingbull.com/disclaimer
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers’ trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers.
RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.
*Sponsored Content:If you purchase anything through a link in this email other than RagingBull (RB) services, you should assume that we have an affiliate relationship with the company providing the product that you purchase, and that we will be paid in some way. RB is not responsible for any content hosted on affiliate’s sites and it is the affiliate’s responsibility to ensure compliance with applicable laws. We recommend that you do your own independent research before purchasing anything. While we believe in the companies we form affiliate relationships with, please don’t spend any money on these products unless you believe they will help you achieve your goals.
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.
